Lunai Bioworks Inc.
LNAILunai Bioworks Inc. in brief
Lunai Bioworks Inc. is a listed company in the Biotechnology industry, based in Suite 906 Los Angeles, California, USA. Its market value was $1 M on 28 October 2026, which makes it the 27,958th largest listed company in the world and the 4,514th largest in the USA on this site. In the year to June 2026 it had sales of $0 M and a net loss of $4 M. It employs about 12 people. Its shares trade under the symbol LNAI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Lunai Bioworks Inc.
As of June 30, 2026, Lunai Bioworks Inc. operated principally through two operating subsidiaries, Renovaro Biosciences and BioSymetrics; a third wholly owned subsidiary, Lunai Bioworks IP, Inc., holds the intellectual property acquired in the May 2026 Neurobridge acquisition, including the N2B intranasal drug delivery platform. BioSymetrics refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025.
During the quarter ended September 30, 2025, GEDi Cube B.V., acquired on February 13, 2024, filed for bankruptcy and ceased operations. Following GEDi Cube's bankruptcy and subsequent deconsolidation, the Company continued pursuing its AI-driven precision medicine and biomarker discovery strategy through BioSymetrics, which had been acquired prior to the bankruptcy. BioSymetrics' existing AI and machine-learning platform provided capabilities that overlapped with GEDi Cube's cancer diagnostics and biomarker discovery objectives while supporting a broader range of applications, including therapeutic development, central nervous system disorders, and biodefense. Using its independently developed technology, BioSymetrics continued pursuing cancer-related diagnostic and biomarker opportunities while expanding the Company's research and business development activities into additional therapeutic areas. Accordingly, GEDi Cube's bankruptcy did not represent a change in the Company's overall strategic direction, as its AI-driven biomedical research and development strategy continued and expanded through BioSymetrics. Following GEDi Cube's deconsolidation, the Company's consolidated operations consisted principally of Renovaro Biosciences' cell and gene therapy programs and BioSymetrics' AI-driven biotechnology platform.
From the company's annual report filed with the US SEC: read the report
Lunai Bioworks Inc. timeline
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- ✎Renamed DanDrit Biotech USA, Inc.Formerly Putnam Hills Corp..
- 2018
- ✎Renamed Enochian Biosciences IncFormerly DanDrit Biotech USA, Inc..
- 2023
- ✎Renamed Renovaro Biosciences Inc.Formerly Enochian Biosciences Inc.
- 2024
- ✎Renamed Renovaro Inc.Formerly Renovaro Biosciences Inc..
- 2025
- ✎Renamed Lunai Bioworks Inc.Formerly Renovaro Inc..
Events of Lunai Bioworks Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,348 (Oct 2026) · #4,517 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 25.2×
- Price / book
- —
- Free cash flow yield
- -419.8%
- Net margin (TTM)
- -7120.0%
- Operating margin
- -17400.0%
- Return on equity
- —
- Liabilities / assets
- 190.8%
- Revenue growth
- +25.0%
- R&D / revenue
- 40.0%
- Revenue per employee
- $4 K
- Profit per employee
- $-297 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $0M | — | $-9M | $-4M | -7120.0% |
| Jun 2025 | — | — | $-189M | $-178M | — |
| Jun 2024 | — | — | $-82M | $-88M | — |
| Jun 2023 | — | — | $-39M | $-40M | — |
| Jun 2022 | — | — | $-116M | $-113M | — |
| Jun 2021 | — | — | $-23M | $-27M | — |
| Jun 2020 | — | — | $-12M | $-11M | — |
| Jun 2019 | — | — | $-11M | $-18M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2026 | $-5M | $0M | $-5M | $-1.06 | — |
| Jun 2025 | $-8M | — | — | $-86.27 | — |
| Jun 2024 | $-11M | $0M | $-11M | $-0.91 | — |
| Jun 2023 | $-12M | $0M | $-12M | $-0.71 | — |
| Jun 2022 | $-16M | $0M | $-16M | $-2.16 | — |
| Jun 2021 | $-21M | $0M | $-21M | $-0.57 | — |
| Jun 2020 | $-10M | $0M | $-11M | $-0.25 | — |
| Jun 2019 | $-9M | $1M | $-9M | $-0.48 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportDirectors or officers changed
- Oct 23, 20268-KCurrent reportListing notice · Directors or officers changed · Regulation FD disclosure · Other events
- Oct 13, 202610-KAnnual report · period to Jun 2026
- Oct 9, 20268-KCurrent reportOther events
- Jun 17, 20268-KCurrent reportOther events
- Jun 16, 20268-KCurrent reportOther events
- May 20, 20268-KCurrent reportOther events
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportShareholder vote
- May 11, 20268-K/ACurrent report (amended)Listing notice
- May 1, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Listing notice · Unregistered share sale · Bylaws amended
- Apr 28, 20268-KCurrent reportOther events
Official filings of Lunai Bioworks Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-9 M
- Net income
- $-4 M
For year ending June-2026 · source: SEC filing
Balance sheet
- Total assets
- $10 M
- Total liabilities
- $19 M
- Total equity
- $-9 M
As of June-2026
Top 17 institutional investors in Lunai Bioworks Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 49,977 | +33,896 (+210.78%) | 0.99% | $0 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 41,514 | +17,358 (+71.86%) | 0.82% | $0 M | Nov 6, 2026 |
| 3 | State Street Corp | 37,537 | 0 (0.00%) | 0.75% | $0 M | Nov 12, 2026 |
| 4 | Jane Street Group, LLC | 21,635 | -2,048 (-8.65%) | 0.43% | $0 M | Nov 12, 2026 |
| 5 | BlackRock, Inc. | 15,906 | 0 (0.00%) | 0.32% | $0 M | Nov 13, 2026 |
| 6 | UBS Group AG | 12,234 | New | 0.24% | $0 M | Nov 10, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 8,642 | 0 (0.00%) | 0.17% | $0 M | Nov 13, 2026 |
| 8 | Tower Research Capital LLC (TRC) | 3,035 | +1,630 (+116.01%) | 0.06% | $0 M | Nov 16, 2026 |
| 9 | Morgan Stanley | 326 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 10 | BNP Paribas Financial Markets | 24 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 11 | Jacobi Capital Management LLC | 10 | New | 0.00% | $0 M | Nov 5, 2026 |
| 12 | Jpmorgan Chase & Co | 6 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 13 | Caitong International Asset Management Co., Ltd | 6 | New | 0.00% | $0 M | Oct 29, 2026 |
| 14 | Royal Bank Of Canada | 5 | -1,682 (-99.70%) | 0.00% | $0 M | Nov 16, 2026 |
| 15 | Barclays PLC | 4 | New | 0.00% | $0 M | Nov 6, 2026 |
| 16 | Group One Trading LLC | 1 | -543 (-99.82%) | 0.00% | $0 M | Nov 10, 2026 |
| 17 | Deutsche Bank AG\ | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Lunai Bioworks Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 13,363 | $0 M | 0.27% | <0.01% | +43% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 12,063 | $0 M | 0.24% | <0.01% | +0.0% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 1,898 | $0 M | 0.04% | <0.01% | −0.0% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,754 | $0 M | 0.03% | <0.01% | −0.0% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 1,157 | $0 M | 0.02% | <0.01% | −0.0% | May 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 23 | $0 M | <0.01% | <0.01% | −76% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Lunai Bioworks Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Anderson Wittekind William10% owner | Other | -350,000 | — | — | 3.35 M | Form 4 |
| filed | Maurice Van TilburgDirector | Grant or award | +250,000 | — | — | 250,000 | Form 4 |
| filed | David Hershel WeinsteinChief Executive Officer, Director | Grant or award | +250,000 | — | — | 250,000 | Form 4 |
| filed | Avram MillerDirector | Disposal to the company | -833,333 | — | — | 166,667 | Form 4 |
| filed | Karen BrinkDirector, 10% owner | Otherindirect · amended | +2.00 M | — | — | 25.37 M | Form 4/A |
| filed | Karen BrinkDirector, 10% owner | Otherindirect | -2.00 M | — | — | 23.37 M | Form 4 |
| filed | Anderson Wittekind William10% owner | Sellindirect | -1,114 | $1.300 | $1 K | 840,319 | Form 4 |
| filed | Anderson Wittekind William10% owner | Sellindirect | -16,362 | $1.460 | $24 K | 841,433 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Lunai Bioworks Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-10-09 18:06 UTC, code LUDP, resumed 18:16 UTC
- 2026-05-21 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-03-26 13:37 UTC, code LUDP, resumed 13:42 UTC
Fails to deliver
- : 3,202 shares at $0.25
- : 118,293 shares at $0.29
- : 5,011 shares at $0.47
- : 471 shares at $0.52
- : 425 shares at $0.47
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lunai Bioworks Inc. scorecard#
Passes 1 of the 13 checks that could be worked out. Fiscal year 2026; market cap of Oct 28, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median25.2×Price to sales 25.2× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.06 vs -86.27Diluted EPS -1.06 in fiscal 2026 against -86.27 the year before (report's currency).
- ✓Net income higher than five years earlier-$4 M-$4 M in fiscal 2026 against -$27 M in 2021.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$4 MNet income -$4 M in fiscal 2026.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 4
- ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.11 at the end of fiscal 2026.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-36.2×Operating income -36.2 times interest in fiscal 2026.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
- ✗Altman Z-score outside the distress zone-77.28Z-score -77.28 (distress zone) for fiscal 2026.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year62.9%Diluted shares up 62.9% in fiscal 2026.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Lunai Bioworks Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jun 30, 2026 | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.1—100% | — | — | — | — | — | — | — | — | — | |
| Research and development | 0.0−95.4%47.2% | 0.5−80.2%— | 2.7−35.0%— | 4.2−50.3%— | 8.4−46.7%— | 16r16+235%— | 4.7+87.9%— | 2.5+305%— | 0.6+883%— | 0.1—— | |
| General and administrative | 7.8−56.4%15002% | 18−27.2%— | 25+60.3%— | 15+6.9%— | 14+89.6%— | 7.6r7.7+6.1%— | 7.1−15.4%— | 8.4r8.3+116%— | 3.9r3.6+318%— | 0.9r1.6—— | |
| Operating expenses | 8.7−95.4%16829% | 189+131%— | 82+112%— | 39−66.8%— | 116+396%— | 23+96.3%— | 12+8.5%— | 11+106%— | 5.3r8.2+122%— | 2.4r2.7—— | |
| Operating income | −8.7—−16729% | −189—— | −82—— | −39—— | −116—— | −23—— | −12—— | −11—— | −5.3r−8.2—— | −2.4r−2.7—— | |
| Interest and finance income | — | — | — | — | 0.1+826%— | 0.0−73.8%— | 0.1−31.6%— | 0.1+60.4%— | 0.0—— | — | |
| Interest expense and finance costs | 0.2−67.6%452% | 0.7−28.2%— | 1.0+74.3%— | 0.6+55.7%— | 0.4−1.8%— | 0.4+264%— | 0.1+242412%— | 0.0−100.0%— | 0.1—— | — | |
| Net interest income | — | — | — | −0.1−204%— | 0.1—— | — | — | — | — | — | |
| Other non-operating income (expense) | 5.1−53.1%9877% | 11—— | −6.8r1.0—— | −1.1−143%— | 2.6—— | −3.4−779%— | 0.5—— | −7.0—— | −1.1−668%— | 0.2—— | |
| Income before tax | — | — | — | −40—— | −113—— | −27—— | −11—— | −18—— | −6.4r−9.3—— | −2.2r−2.5—— | |
| Income tax | 0.0−4.6%2.7% | 0.0—— | 0—— | — | 0.0—— | −0.1—— | — | — | −0.1—— | −0.1—— | |
| Net income including minority interests | −3.6—−6852% | −178—— | −88r−81—— | −40—— | — | — | — | — | −9.2—— | −2.5—— | |
| Net income attributable to shareholders | −3.6—−6852% | −178—— | −88r−81—— | −40—— | −113—— | −27—— | −11—— | −18—— | −6.3r−9.2—— | −2.1r−2.4—— | |
| Earnings per share, basic | -1.06—— | -86.27r-1.08—— | -0.91r-0.84—— | -0.71—— | -2.16—— | -0.57—— | -0.25—— | -0.48—— | -0.29r-0.42—— | -0.17r-0.20—— | |
| Earnings per share, diluted | -1.06—— | -86.27r-1.08—— | -0.91r-0.84—— | -0.71—— | -2.16—— | -0.57—— | -0.25—— | -0.48—— | -0.29r-0.42—— | -0.17r-0.20—— | |
| Shares, weighted average (basic) | 3.4+62.9%— | 2.1r165−97.9%— | 98r96+73.3%— | 56+7.1%— | 53—— | — | — | — | — | 12—— | |
| Shares, weighted average (diluted) | 3.4+62.9%— | 2.1r165−97.9%— | 98r96+73.3%— | 56+7.1%— | 53+11.4%— | 47+1.8%— | 46+23.4%— | 38+71.2%— | 22+78.9%— | 12—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1.7+1749%17.2% | 0.1−58.0%1.1% | 0.2−88.2%0.1% | 1.9−79.6%3.2% | 9.2−55.6%10.8% | 21+138%10.9% | 8.7−29.2%4.9% | 12−21.3%6.8% | 16+296%8.5% | 3.9—87.2% | |
| Other current assets | — | — | 0.7—0.4% | — | 0.4—0.5% | — | — | — | — | — | |
| Current assets | 2.0+94.6%20.5% | 1.0−47.6%12.7% | 2.0−22.1%1.2% | 2.6−73.2%4.4% | 9.6−54.2%11.3% | 21+134%11.0% | 8.9−28.4%5.0% | 12−20.7%6.9% | 16+275%8.6% | 4.2—92.9% | |
| Property, plant and equipment | 0.0−96.7%0.1% | 0.4−23.7%4.5% | 0.5−5.3%0.3% | 0.5−13.2%0.9% | 0.6−18.5%0.7% | 0.7−7.6%0.4% | 0.8+13.2%0.4% | 0.7+2409%0.4% | 0.0—0.0% | — | |
| Right-of-use (leased) assets | — | 0.7−45.9%8.4% | 1.3+38.9%0.8% | 0.9−21.0%1.6% | 1.2−19.4%1.4% | 1.4−15.7%0.8% | 1.7—1.0% | — | — | — | |
| Goodwill | 6.00.0%60.0% | 6.0−96.3%72.4% | 159+1269%97.7% | 120.0%20.0% | 120.0%13.8% | 120.0%6.1% | 120.0%6.5% | 120.0%6.5% | 12—6.4% | — | |
| Other intangible assets | 1.4+752%14.2% | 0.2+453%2.0% | 0.0−24.3%0.0% | 0.0−10.4%0.1% | 0.0−32.8%0.1% | 0.1−14.8%0.0% | 0.1−17.1%0.0% | 0.1−99.9%0.1% | 148r150+119083%81.2% | 0.1—2.8% | |
| Non-current assets | — | — | — | — | — | — | 168+1.0%94.5% | 167−0.0%92.7% | 167r164+51471%91.3% | 0.3—7.1% | |
| Total assets | 9.9+20.8%100% | 8.2−95.0%100% | 163+180%100% | 58−31.1%100% | 85−55.4%100% | 190+6.5%100% | 178−1.0%100% | 180−1.4%100% | 183r180+3936%100% | 4.5—100% | |
| Accounts payable | 12−1.3%125% | 13+32.9%153% | 9.4+78.4%5.8% | 5.3+278%9.1% | 1.4+337%1.7% | 0.3−45.9%0.2% | 0.6+10.1%0.3% | 0.5−5.8%0.3% | 0.6+31.5%0.3% | 0.4—9.6% | |
| Current liabilities | 19−35.1%190% | 29−3.8%354% | 30+175%18.6% | 11+70.9%18.9% | 6.5+242%7.6% | 1.9+41.3%1.0% | 1.3+20.2%0.7% | 1.1+27.1%0.6% | 0.9−70.8%0.5% | 3.0—66.1% | |
| Lease liabilities (non-current) | 0.1−86.8%0.6% | 0.4−49.6%5.2% | 0.8+8.6%0.5% | 0.8−21.3%1.3% | 1.0−20.5%1.2% | 1.2−19.1%0.7% | 1.5—0.9% | — | — | — | |
| Non-current liabilities | 0.1−86.8%0.6% | 0.4−49.6%5.2% | 0.8+8.6%0.5% | 0.8−86.1%1.3% | 5.6−57.4%6.6% | 13r15+10.4%6.9% | 12—6.6% | — | — | — | |
| Total liabilities | 19−35.9%191% | 30−5.0%359% | 31+164%19.1% | 12−1.8%20.2% | 12−19.6%14.2% | 15+26.3%7.9% | 12+74.5%6.6% | 6.8−71.5%3.8% | 24+695%13.0% | 3.0—66.1% | |
| Retained earnings | −514—−5170% | −510—−6202% | −332r−325—−204% | −244—−419% | −204—−241% | −91—−47.9% | −64—−36.0% | −53—−29.3% | −35r−38—−19.0% | −28r−29—−629% | |
| Shareholders' equity | −9.0—−90.8% | −21−116%−259% | 132+184%80.9% | 47−36.0%79.8% | 73−58.4%85.8% | 175+5.0%92.1% | 166−3.9%93.4% | 173+9.0%96.2% | 159r156+10257%87.0% | 1.5—33.9% | |
| Total equity | — | — | 132+184%80.9% | 47—79.8% | — | — | — | — | — | — | |
| Total liabilities and equity | 9.9+20.8%100% | 8.2−95.0%100% | 163+180%100% | 58−31.1%100% | 85−55.4%100% | 190+6.5%100% | 178−1.0%100% | 180−1.4%100% | 183r180+3936%100% | 4.5—100% | |
| Shares outstanding | 4.6+108%— | 2.2r177−98.6%— | 158r155+149%— | 64+20.2%— | 53+1.5%— | 52+12.3%— | 46+2.7%— | 45+25.2%— | 36+191%— | 12—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1−27.6%180% | 0.1+5.9%— | 0.1+7.4%— | 0.1−8.2%— | 0.1+0.0%— | 0.1+13.8%— | 0.1+51.4%— | 0.1+288%— | 0.0r2.9+27.2%— | 0.0—— | |
| Share-based compensation | 0.6−81.0%1212% | 3.3−29.1%— | 4.7+32.2%— | 3.5−32.5%— | 5.2+304%— | 1.3+46.7%— | 0.9−58.4%— | 2.1+3235%— | 0.1r0.2−89.8%— | 0.6—— | |
| Cash from operating activities | −5.3—−10171% | −7.9—— | −11—— | −12—— | −16—— | −21—— | −10—— | −8.5—— | −4.3—— | −1.2—— | |
| Capital expenditure | −0.0—−2.4% | — | −0.1—— | −0.0—— | −0.0—— | −0.0—— | −0.2—— | −0.7—— | −0.0—— | — | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | −0.3—— | — | |
| Cash from investing activities | 0.5—1045% | −0.5—— | −1.3—— | −0.0—— | −0.0—— | −0.0—— | −0.2—— | −0.7—— | −0.6—— | −0.2—— | |
| Debt issued | 5.0—9709% | 0−100%— | 3.8—— | 0—— | — | — | — | — | — | — | |
| Shares issued | — | — | — | — | — | 0.1—— | — | — | 17+376%— | 3.5—— | |
| Cash from financing activities | 6.4−23.8%12293% | 8.4−20.3%— | 11+133%— | 4.5+6.2%— | 4.3−87.0%— | 33+353%— | 7.2+19.6%— | 6.0−64.0%— | 17+204%— | 5.5—— | |
| Exchange-rate effect on cash | −0.0—−49.6% | −0.1−326%— | 0.1—— | −0.0—— | −0.0−120%— | 0.0—— | −0.1—— | −0.1—— | −0.1—— | −0.2—— | |
| Change in cash | 1.6—3118% | −0.1—— | −1.7—— | −7.3—— | −11−196%— | 12—— | −3.6—— | −3.3−128%— | 12+198%— | 3.9—— | |
| Report | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q4 FY2026to Jun 30, 2026 | Q3 FY2026to Mar 31, 2026 | Q2 FY2026to Dec 31, 2025 | Q1 FY2026to Sep 30, 2025 | Q4 FY2025to Jun 30, 2025 | Q3 FY2025to Mar 31, 2025 | Q2 FY2025to Dec 31, 2024 | Q1 FY2025to Sep 30, 2024 | Q4 FY2024to Jun 30, 2024 | Q3 FY2024to Mar 31, 2024 | Q2 FY2024to Dec 31, 2023 | Q1 FY2024to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 0.0*—100% | 0.0—100% | — | — | — | — | — | — | — | — | — | — | |
| Gross profit | — | — | 0.0—100% | — | — | — | — | — | — | — | — | — | — | |
| Research and development | — | — | 0.0—76.1% | 0.0−71.5%— | 0.0−93.7%— | — | — | 0.2−74.0%— | 0.4−31.1%— | 0.4*—— | 1.1—— | 0.6—— | 0.6—— | |
| General and administrative | 7.8−56.4%— | 2.2*−45.0%7092% | 1.4−66.4%6787% | 1.8−59.4%— | 2.4−54.5%— | 4.0*−20.0%— | 4.2−44.8%— | 4.4+20.4%— | 5.3−36.1%— | 5.0*—— | 7.7—— | 3.6—— | 8.3—— | |
| Operating expenses | 8.7−95.4%— | 2.2*−98.3%6989% | 1.4−65.2%6915% | 1.8−59.9%— | 3.3−93.8%— | 127*+642%— | 4.2−91.9%— | 4.5+6.5%— | 53+500%— | 17*—— | 51r17—— | 4.3—— | 8.9—— | |
| Operating income | −8.7—— | −2.1*—−6889% | −1.5—−7054% | −1.8—— | −3.3—— | −127*—— | −4.2—— | −4.5—— | −53—— | −17*—— | −51r−17—— | −4.3—— | −8.9—— | |
| Interest expense and finance costs | — | — | 0.1−42.7%516% | 0.1+22.9%— | 0.1−51.1%— | 0.2*−25.8%— | 0.2−37.9%— | 0.1−64.0%— | 0.3+39.5%— | 0.3*—— | 0.3—— | 0.3—— | 0.2—— | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | — | 0.0—— | 0.0—— | |
| Other non-operating income (expense) | 5.1−53.1%— | 0.1*−31.2%413% | −1.1−126%−5463% | 0.0—— | 6.1−32.9%— | 0.2*−86.4%— | 4.4r4.4—— | −2.7—— | 9.1—— | 1.4r1.4*—— | −7.6r0.2—— | −0.3—— | −0.3—— | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | — | −9.2—— | |
| Net income including minority interests | — | — | — | −1.8—— | 2.8—— | −127*—— | 0.2—— | −7.3—— | −44—— | −16*—— | −59—— | −4.5—— | −9.2—— | |
| Net income attributable to shareholders | −3.6—— | −2.0*—−6476% | −2.6−1459%−12279% | −1.8—— | 2.8—— | −127*—— | 0.2—— | −7.3—— | −44r−44—— | −16r−16*—— | −59r−17—— | −4.5—— | −9.2—— | |
| Earnings per share, basic | — | — | -0.10—— | -0.08—— | 0.13—— | — | 0.00—— | -0.45r-0.04—— | -2.76r-0.28—— | — | -0.54r-0.16—— | -0.07—— | -0.14—— | |
| Earnings per share, diluted | — | — | -0.10—— | -0.08—— | 0.13—— | — | 0.00—— | -0.45r-0.04—— | -2.76r-0.28—— | — | -0.54r-0.16—— | -0.07—— | -0.14—— | |
| Shares, weighted average (basic) | — | — | 25+54.0%— | 23+45.1%— | 23+40.8%— | — | 16r162−85.1%— | 16r162−75.4%— | 16r157−75.2%— | — | 109r107—— | 66—— | 64—— | |
| Shares, weighted average (diluted) | — | — | 25+52.5%— | 23+45.1%— | 23+40.8%— | — | 16r164−85.0%— | 16r162−75.4%— | 16r157−75.2%— | — | 109r107—— | 66—— | 64—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 1.7—17.2% | 1.7+1749%17.2% | 3.2+242%32.0% | 0.5+57.7%7.4% | 0.6+183%9.0% | 0.1−58.0%1.1% | 0.9+195%0.8% | 0.3+27.8%0.3% | 0.2−57.9%0.2% | 0.2—0.1% | 0.3—0.2% | 0.2—0.4% | 0.5—0.9% | |
| Receivables | — | — | — | — | — | — | 1.0—0.8% | — | — | — | — | 1.1—1.9% | 1.1—1.8% | |
| Other current assets | — | — | — | — | — | — | 0.9—0.8% | 1.3—1.1% | 0.5—0.4% | 0.7—0.4% | — | — | — | |
| Current assets | 2.0—20.5% | 2.0+94.6%20.5% | 3.7+1.8%37.9% | 0.5−69.9%7.7% | 0.8−58.9%11.5% | 1.0−47.6%12.7% | 3.7+201%3.1% | 1.7−28.9%1.5% | 1.9+2.2%1.6% | 2.0—1.2% | 1.2—0.7% | 2.4—4.1% | 1.9—3.3% | |
| Property, plant and equipment | 0.0—0.1% | 0.0−96.7%0.1% | 0.0−96.7%0.1% | 0.0−96.9%0.2% | 0.0−97.2%0.2% | 0.4−23.7%4.5% | 0.4−19.6%0.3% | 0.4−15.1%0.4% | 0.5−6.3%0.4% | 0.5—0.3% | 0.5—0.3% | 0.5—0.9% | 0.5—0.8% | |
| Right-of-use (leased) assets | — | — | — | — | — | 0.7−45.9%8.4% | 1.0−28.4%0.8% | 1.2+45.3%1.1% | 1.2+33.2%0.9% | 1.3—0.8% | 1.4—0.8% | 0.8—1.4% | 0.9—1.5% | |
| Goodwill | 6.0—60.0% | 6.00.0%60.0% | 6.0−94.7%60.5% | 6.0−94.5%89.4% | 6.0−95.0%85.7% | 6.0−96.3%72.4% | 113−31.4%95.7% | 108+828%97.0% | 118+915%97.0% | 159—97.7% | 164—92.2% | 12—20.1% | 12—20.2% | |
| Other intangible assets | 1.4—14.2% | 1.4+752%14.2% | 0.1+637%1.2% | 0.1+696%2.1% | 0.2+432%2.2% | 0.2+453%2.0% | 0.0−47.9%0.0% | 0.0−45.3%0.0% | 0.0−23.6%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.1% | 0.0—0.1% | |
| Total assets | 9.9—100% | 9.9+20.8%100% | 9.9−91.6%100% | 6.7−94.0%100% | 7.0−94.3%100% | 8.2−95.0%100% | 118−33.9%100% | 111+91.9%100% | 122+112%100% | 163—100% | 178r212—100% | 58—100% | 58—100% | |
| Accounts payable | 12—125% | 12−1.3%125% | 13+8.1%129% | 12+12.8%185% | 12+6.1%174% | 13+32.9%153% | 12+46.7%10.0% | 11+96.0%9.8% | 11+110%9.4% | 9.4—5.8% | 8.0—4.5% | 5.6—9.6% | 5.4—9.4% | |
| Current liabilities | 19—190% | 19−35.1%190% | 19−33.1%196% | 20−30.1%300% | 20−14.4%283% | 29−3.8%354% | 29+38.2%24.5% | 29+108%25.7% | 23+128%18.9% | 30—18.6% | 21—11.7% | 14—23.7% | 10—17.5% | |
| Lease liabilities (non-current) | 0.1—0.6% | 0.1−86.8%0.6% | 0.1−73.6%1.3% | 0.2−68.3%3.2% | 0.3−60.7%4.0% | 0.4−49.6%5.2% | 0.5−48.7%0.4% | 0.7+1.5%0.6% | 0.7−1.5%0.6% | 0.8—0.5% | 1.0—0.5% | 0.7—1.1% | 0.7—1.3% | |
| Non-current liabilities | 0.1—0.6% | 0.1−86.8%0.6% | 0.1−73.6%1.3% | 0.2−68.3%3.2% | 0.3−60.7%4.0% | 0.4−49.6%5.2% | 0.5−97.8%0.4% | 0.7+1.5%0.6% | 0.7−1.5%0.6% | 0.8—0.5% | 23—12.8% | 0.7—1.1% | 0.7—1.3% | |
| Total liabilities | 19—191% | 19−35.9%191% | 19−33.8%197% | 20−31.0%303% | 20−15.8%287% | 30−5.0%359% | 29−32.8%24.9% | 29+103%26.3% | 24+120%19.5% | 31—19.1% | 44—24.5% | 14—24.9% | 11—18.8% | |
| Retained earnings | −514—−5170% | −514—−5170% | −512—−5193% | −509—−7642% | −508—−7293% | −510—−6202% | −384—−326% | −384—−345% | −377r−369—−309% | −332r−325—−204% | −317r−275—−178% | −258—−444% | −253—−440% | |
| Shareholders' equity | −9.0—−90.8% | −9.0—−90.8% | −9.6−111%−96.9% | −14−117%−203% | −13−113%−187% | −21−116%−259% | 88r88−34.2%75.1% | 82r82+88.2%73.7% | 98r98+110%80.5% | 132—80.9% | 134r169—75.5% | 44—75.1% | 47—81.2% | |
| Total equity | — | — | — | — | — | — | 88−34.2%75.1% | 82+88.2%73.7% | 98+110%80.5% | 132—80.9% | 134—75.5% | 44—75.1% | 47—81.2% | |
| Total liabilities and equity | 9.9—100% | 9.9+20.8%100% | 9.9−91.6%100% | 6.7−94.0%100% | 7.0−94.3%100% | 8.2−95.0%100% | 118−33.9%100% | 111+91.9%100% | 122+112%100% | 163—100% | 178r212—100% | 58—100% | 58—100% | |
| Shares outstanding | 4.6—— | 4.6+108%— | 36−78.0%— | 24−85.1%— | 23−85.6%— | 2.2r177−98.6%— | 162+7.6%— | 162+141%— | 161r158+145%— | 158r155—— | 151r147—— | 67—— | 66—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−30.6%— | 0.0*−22.7%95.5% | 0.0−65.6%52.5% | 0.0−64.7%— | 0.0+28.2%— | 0.0r0.0*+23.2%— | 0.0+5.5%— | 0.0−3.2%— | 0.0+18.8%— | 0.0*—— | 0.0—— | 0.0—— | 0.0—— | |
| Share-based compensation | 0.6−81.0%— | 0.2*−83.2%487% | 0.2−88.7%807% | 0.1−76.9%— | 0.2−49.3%— | 0.9*+8.4%— | 1.5−19.5%— | 0.6−44.1%— | 0.4−63.6%— | 0.8*—— | 1.9—— | 1.0—— | 1.0—— | |
| Cash from operating activities | −5.3—— | −1.8*—−5929% | −1.0*—−4903% | −1.1*—— | −1.3—— | −1.8*—— | −1.5*—— | −2.6*—— | −2.0—— | −2.4*—— | −2.6*—— | −3.1*—— | −2.8—— | |
| Capital expenditure | — | 0*—0.0% | 0*—0.0% | — | — | — | — | — | — | −0.0*—— | −0.0*—— | — | — | |
| Cash from investing activities | 0.5—— | 0*−100%0.0% | 0*—0.0% | −0.0*—— | 0.5—— | 1.0*—— | — | — | 0—— | −0.1*—— | −0.1*—— | −0.1*—— | −1.1—— | |
| Debt issued | — | — | — | — | — | — | — | — | — | 0.1*—— | 1.1*—— | — | — | |
| Cash from financing activities | 6.4−23.8%— | 0.4*+121%1271% | 3.7*+3.3%17685% | 1.0*−63.3%— | 1.3−33.8%— | 0.2*−92.8%— | 3.6*+35.7%— | 2.6*−9.0%— | 2.0−20.8%— | 2.5*—— | 2.6*—— | 2.8*—— | 2.6—— | |
| Exchange-rate effect on cash | −0.0—— | 0.0*—15.5% | −0.0*—−62.2% | −0.0*−118%— | −0.0—— | −0.2*—— | −0.0*−114%— | 0.1*−22.8%— | −0.0—— | −0.1*—— | 0.2*—— | 0.1*—— | −0.1—— | |
| Change in cash | 1.6—— | −1.4*—−4643% | 2.7*+336%12719% | −0.1*−246%— | 0.5+511542%— | −0.8*—— | 0.6*+790%— | 0.1*—— | 0.0—— | −0.1*—— | 0.1*—— | −0.3*—— | −1.4—— | |
| Report | Worked out | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q/A | 10-K | 10-Q/A | 10-Q | 10-Q/A | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Lunai Bioworks Inc. operates: 4 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office3 subsidiaries | — |
| 🇩🇰 Denmark | 1 subsidiary | — |
| 🇳🇱 Netherlands | 1 subsidiary | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Lunai Bioworks Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
- Delisting noticeFiling
- Delisting noticeFiling
- Delisting noticeFiling
- Delisting noticeFiling
- Delisting noticeFiling
And 5 more in the list below.
Delisting notice 10 · Impairment 1 · Taken over and delisted 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 5 · Unregistered share sale 5 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Delisting noticeDirectors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K/A | |
| Taken over and delistedAcquisition or sale completedMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Unregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Impairment | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2024 | $107 M | Private placement after listing | $50 to $250 million | 8 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Lunai Bioworks Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2026, most often on defense.
- Defense3 reports
Lobbying firms hired in 2026
American Defense International, Inc. $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $20 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Lunai Bioworks, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Lunai Bioworks Inc. compares in Biotechnology
- Market cap$1 M · higher than 1% of 726
- Revenue$0 M · higher than 15% of 647
- Price / sales25.2× · lower than 27% of 339
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Lunai Bioworks Inc.🇺🇸 | $1 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending June-2026
- Balance sheet:
- As of June-2026
- Employees:
- As of June 30, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Lunai Bioworks Inc.? Verify and update this profile — free
Show Lunai Bioworks Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.